Elsevier

Seminars in Oncology

Volume 43, Issue 1, February 2016, Pages 65-77
Seminars in Oncology

Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention

https://doi.org/10.1053/j.seminoncol.2015.09.010Get rights and content

Abstract

Various clinical and epidemiologic studies show that nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin and cyclooxygenase inhibitors (COXIBs) help prevent cancer. Since eicosanoid metabolism is the main inhibitory targets of these drugs the resulting molecular and biological impact is generally accepted. As our knowledge base and technology progress we are learning that additional targets may be involved. This review attempts to summarize these new developments in the field.

Introduction

Recent secondary meta-analyses of large randomized clinical trials [1], [2], [3], [4], [5], [6], [7], [8] provide strong evidence for the cancer preventive effects of aspirin in reducing the incidence [9], mortality [10], and metastasis [10] of gastrointestinal and other cancers, especially adenocarcinomas. These data were recently reviewed in other publications [3], [4], [6], [8], [9], [10], [11]. Although various potential mechanisms may be responsible for aspirin’s preventive effects, the primary molecular pathway receiving general acceptance involves prostaglandins. Additional mechanisms are beginning to gain recognition, while others remain unknown since aspirin covalently acetylates many different molecules, which may serve as possible targets (Table 1) [12], [13], [14]. New insights into the mechanisms of aspirin’s action(s) may also be realized with recent advances in technology [15], [16], [17]. Hence, this article attempts to outline the most plausible mechanisms and supportive evidence underlying the cancer preventive efficacy of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs).

Aspirin is among the most successful drugs in history. It also serves as a key example of a commonly used anti-inflammatory drug with significant cancer preventive benefits. Thus, although aspirin is currently recommended for secondary prevention of cardiovascular disease (CVD) [18]; it may also be used for primary prevention in specific subsets of patients whose risk of serious bleeding does not outweigh the benefits estimated by the CVD indication [18], [19]. Analysis of 51 randomized controlled trials (RCTs) showed strong evidence that aspirin reduced cancer-associated mortality and prevented CVD when used daily (odds ratio [OR], 0.85; 95% confidence interval [CI], 0.76–0.96; P = .008) [10]. Overall, this beneficial effect was enhanced after 5 years (OR, 0.63; 95% CI, 0.49–0.82; P = .0005). Six trials also showed reduced cancer incidence after 3 years of use (OR, 0.76; 95% CI, 0.66–0.88; P = .0003). The reduction was most pronounced for gastrointestinal cancers, with a hazard ratio (HR) of 0.46 (95% CI, 0.27–0.77; P = .003), and was statistically significant for esophagus, colon, and lung cancers. All cancer preventive effects, including effects on incidence, mortality, and metastasis, increased with scheduled trial-treatment duration. Importantly, all case-fatality from major extra cranial bleeds was lower in aspirin than controls (OR, 0.32, 95% CI, 0.12–0.83; P = .009), suggesting a favorable risk:benefit ratio. Observational studies have also demonstrated reductions in cancer incidence [20], especially for cancers of the gastrointestinal tract, as well as for cancer-related [21], [22], [23] and all-cause mortality [21], [22], [24].

Earlier evidence that NSAIDs and aspirin prevent cancer came from multiple clinical trials involving short-term aspirin use at varying doses that produced a favorable outcome against colorectal adenomas. For example, in patients with a prior history of colorectal cancer (CRC) [25] or colorectal adenomas [26], [27], patients taking aspirin had a reduction in new adenomas when compared to the aspirin-free subset. The Colorectal Adenoma/Carcinoma Prevention Programme (CAPP) trial found that the long-term effects of aspirin using an intent-to-treat analysis for CRC indicated an HR of 0.63 (95% CI, 0.35–1.13; P = .12) in a specialized population with hereditary CRC (Lynch syndrome) [28].

In addition to aspirin, other NSAIDs and cyclooxygenase inhibitors (COXIBs) exhibited efficacy in CRC prevention trials. For example, celecoxib, a selective inhibitor of cyclooxygenase-2 (COX-2), inhibited adenoma formation in high-risk patients with familial adenomatous polyposis (FAP) [29] and in patients following polypectomy [30], [31]. However, due to the cardiovascular toxicity observed in cancer prevention trials, rofecoxib and some other COX-2-selective inhibitors were pulled off the market [32], [33], [34] and although effective, those remaining on the market are not currently considered appropriate for cancer prevention purposes. Even with these setbacks, promising cancer preventive efficacy was observed in a phase III trial in which individuals with a history of adenomas were randomized to the NSAID sulindac used in combination with difluoromethylornithine (DFMO), an ornithine decarboxylase inhibitor. In those receiving the combination, both recurrent (relative risk [RR], 0.30; 95% CI, 0.18–0.49; P <.001) and advanced adenomas (RR, 0.085; 95% CI, 0.011–0.65; P <.001) were significantly and markedly reduced compared to placebo [35]. When considered together, these studies strongly suggest an overall role for aspirin and other NSAIDs as a class of drugs for reducing colon cancer risk. Key observations from recent analyses are summarized below:

  • 1.

    Adequate evidence shows a reduction in the incidence and mortality of a range of cancers associated with aspirin/NSAID use, especially in the gastrointestinal tract, with the strongest evidence for esophageal adenocarcinoma (30%–50%) and colorectal cancer (25–35%).

  • 2.

    Good evidence shows a reduction in stomach cancer (25%–40%); however, there is a much smaller effect on breast, prostate and lung cancer prevention.

  • 3.

    Little or no effect appears in existing data on other major cancer sites including pancreatic, endometrial, and hematopoietic tumors.

  • 4.

    The overall effect of regular long-term use of aspirin is a 20%–25% reduction in cancer incidence and mortality; the effect on incidence is not apparent until after 3 years of use; the effect on mortality is not apparent until after 5 years of use.

  • 5.

    Aspirin reduces the incidence of cardiovascular events by 15%–20%, both in the general population and in high-risk groups. However, with increasing awareness of risk factors and the wide range of effective agents available for the high-risk individuals, use of aspirin in the general population does not have a major impact on cardiovascular mortality.

  • 6.

    Not only is the risk of peptic ulcer and gastrointestinal (GI) bleeding age-dependent, but the seriousness of the outcome (proportion of fatal events) is also much greater in older individuals. The major risk of aspirin use (ie, GI bleeding), is associated with much less morbidity and lower mortality among individuals younger than 65 years.

  • 7.

    Overall mortality is reduced in aspirin users.

Despite this progress and decades of research, the precise mechanisms contributing to NSAIDs’ and aspirin’s efficacy in lowering cancer incidence, progression, and metastasis, as well as reducing effects on cancer-associated mortality, remain unclear. Here we outline several leading mechanisms and pathways that may be implicated in the overall benefit seen with aspirin and NSAIDs. Furthermore, in view of the biologic complexities and signaling pathways involved in cancer development, several lines of evidence also suggest that multiple mechanisms are responsible for its broad effects on carcinogenesis.

Section snippets

2. Possible mechanisms for cancer prevention using NSAIDs and/or aspirin

Ample evidence from various sources supports inflammation as playing a role in the initiation, progression, and development of cancer. Inflammation is a hallmark of cancer (see Ryan and Faupel-Badger, this issue) [36], [37]; therefore, it is quite possible that simply targeting anti-inflammatory processes might reduce cancer incidence and cancer-associated mortality. Many cancers are associated with chronic inflammatory diseases (eg, inflammatory bowel disease, Crohn’s and colitis, both viral

3. Aspirin and NSAIDs for cancer prevention

Aspirin and NSAIDs have been extensively tested preclinically in mice and rats after either genetic or chemical induction of carcinogenesis. Briefly, the experience with aspirin has been mixed where mice show somewhat different pharmacokinetics and efficacy, where these animals seem to show dose dependency as well as efficacy at much higher doses than equivalent doses in humans [139], [197], [211]. Regardless of some differences in the dose dependency or actual translation to human cancer

4. Summary

The continued study of the effect of NSAIDs on cancer progression strengthens the notion that COX-dependent mechanisms are primarily involved in this process. Additional studies are revealing that COX-independent pathways may also be involved in prevention of cancer. This point is critical and raises a few major questions: COX-1/2 play key roles in carcinogenesis, and we continue to learn about other valuable targets, but how do we prioritize their importance? And, although COX-2

References (232)

  • J. Burn et al.

    Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial

    Lancet

    (2011)
  • D. Hanahan et al.

    The hallmarks of cancer

    Cell

    (2000)
  • D. Hanahan et al.

    Hallmarks of cancer: the next generation

    Cell

    (2011)
  • E. Kassi et al.

    Glucocorticoid receptor signaling and prostate cancer

    Cancer Lett

    (2011)
  • T. Van Bogaert et al.

    Crosstalk between TNF and glucocorticoid receptor signaling pathways

    Cytokine Growth Factor Rev

    (2010)
  • C.G. Chapman et al.

    The potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease

    Gastrointest Endosc Clin N Am

    (2014)
  • C.E. Eberhart et al.

    Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas

    Gastroenterology

    (1994)
  • C.S. Williams et al.

    Elevated cyclooxygenase-2 levels in Min mouse adenomas

    Gastroenterology

    (1996)
  • R.N. DuBois et al.

    Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors

    Gastroenterology

    (1996)
  • M. Oshima et al.

    Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)

    Cell

    (1996)
  • M.J. Cho et al.

    Chemical stability of prostacyclin (PGI2) in aqueous solutions

    Prostaglandins

    (1978)
  • P. Guillem-Llobat et al.

    Platelets, cyclooxygenases, and colon cancer

    Semin Oncol

    (2014)
  • C. Skarke et al.

    Selective COX-2 inhibitors suppress prostacyclin

    Clin Ther

    (2014)
  • L.M. Lichtenberger et al.

    Insight into NSAID-induced membrane alterations, pathogenesis and therapeutics: characterization of interaction of NSAIDs with phosphatidylcholine

    Biochim Biophys Acta

    (2012)
  • N. Yoshida et al.

    Release of arachidonic acid from human platelets. A key role for the potentiation of platelet aggregability in normal subjects as well as in those with nephrotic syndrome

    Blood

    (1978)
  • A. Derksen et al.

    Patterns of fatty acid release from endogenous substrates by human platelet homogenates and membranes

    J Biol Chem

    (1975)
  • H. Elimam et al.

    Complement-mediated activation of calcium-independent phospholipase A2gamma: role of protein kinases and phosphorylation

    J Biol Chem

    (2013)
  • R.J. Flower et al.

    The importance of phospholipase-A2 in prostaglandin biosynthesis

    Biochem Pharmacol

    (1976)
  • K. Schror et al.

    Transformation of arachidonic acid and prostaglandin endoperoxides by the guinea pig heart. Formation of RCS and prostacyclin

    Eur J Pharmacol

    (1978)
  • L.J. Marnett et al.

    Co-oxygenation of organic substrates by the prostaglandin synthetase of sheep vesicular gland

    J Biol Chem

    (1975)
  • K. Kawahara et al.

    Prostaglandin E-induced inflammation: Relevance of prostaglandin E receptors

    Biochim Biophys Acta

    (2015)
  • W.E. Smalley et al.

    Colorectal cancer and nonsteroidal anti-inflammatory drugs

    Adv Pharmacol

    (1997)
  • K. Watanabe et al.

    Purification and characterization of membrane-bound prostaglandin E synthase from bovine heart

    Biochim Biophys Acta

    (1999)
  • T. Tanioka et al.

    Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis

    J Biol Chem

    (2000)
  • N. Tanikawa et al.

    Identification and characterization of a novel type of membrane-associated prostaglandin E synthase

    Biochem Biophys Res Commun

    (2002)
  • W.Y. Sheng et al.

    Prostaglandin endoperoxide E2 isomerase is dissociated from prostaglandin endoperoxide synthetase in the renal cortex

    J Biol Chem

    (1982)
  • F.G. Russel et al.

    Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules

    Trends Pharmacol Sci

    (2008)
  • K. Hocherl et al.

    COX-2 inhibition attenuates endotoxin-induced downregulation of organic anion transporters in the rat renal cortex

    Kidney Int

    (2009)
  • N. Ohkura et al.

    Gene expression analysis of membrane transport proteins in normal and lipopolysaccharide-inflamed rat dental pulp

    J Endod

    (2012)
  • T.J. Kochel et al.

    Multiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as determinants of PGE levels in cancer

    Prostaglandins Other Lipid Mediat

    (2015)
  • H.H. Tai et al.

    Regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by non-steroidal anti-inflammatory drugs (NSAIDs)

    Prostaglandins Other Lipid Mediat

    (2011)
  • A.T. Chan et al.

    Aspirin in the chemoprevention of colorectal neoplasia: an overview

    Cancer Prev Res (Phila)

    (2012)
  • L.B. Goldstein et al.

    Advances in prevention and health services delivery 2010-2011

    Stroke

    (2012)
  • R.E. Langley et al.

    Potential biomarker for aspirin use in colorectal cancer therapy

    Nat Rev Clin Oncol

    (2013)
  • R.E. Langley et al.

    Aspirin in gastrointestinal oncology: new data on an old friend

    Curr Opin Oncol

    (2014)
  • P.M. Rothwell

    Alternate-day, low-dose aspirin and cancer risk

    Ann Intern Med

    (2013)
  • P.M. Rothwell

    Aspirin in prevention of sporadic colorectal cancer: current clinical evidence and overall balance of risks and benefits

    Recent Results Cancer Res

    (2013)
  • R.N. Pinckard et al.

    In vitro acetylation of plasma proteins, enzymes and DNA by aspirin

    Nature

    (1968)
  • J. Wang et al.

    Mapping sites of aspirin-induced acetylations in live cells by quantitative acid-cleavable activity-based protein profiling (QA-ABPP)

    Sci Rep

    (2015)
  • J. Lei et al.

    Mechanistic insights into a classic wonder drug-aspirin

    J Am Chem Soc

    (2015)
  • Cited by (0)

    View full text